537 possible guidelines found at PubMed. Will restrict search terms to MeSH major headings.
621 possible guidelines found from PubMed (View at PubMed)
- Is Immune Thrombocytopenia and its Treatment Associated with Sarcopenia? Niger J Clin Pract. 2024 PMID: 38409145; Cite
- Thrombopoietin receptor agonists use and risk of thrombotic events in patients with immune thrombocytopenic purpura: A systematic review and meta‑analysis of randomized controlled trials. Biomed Rep. 2024 PMID: 38357229; Cite
- A Review on Romiplostim Mechanism of Action and the Expressive Approach in E. coli. Recent Pat Biotechnol. 2024 PMID: 38282441; Cite
- Long-term eltrombopag in children with chronic immune thrombocytopenia: A single-centre extended real-life observational study in China. Br J Haematol. 2024 PMID: 38087811; Cite
- Avatrombopag for adults with early versus chronic immune thrombocytopenia. Am J Hematol. 2024 PMID: 38063420; Cite
- Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: Primary, final, and ad-hoc analyses of the Phase II TAPER trial. Am J Hematol. 2024 PMID: 38014779; Cite
- Efficacy and safety of eltrombopag in the treatment of immune thrombocytopenia patients with hepatitis B virus infection: A prospective, multicenter, single arm, phase II trial. Am J Hematol. 2024 PMID: 37883528; Cite
- Antithrombotic and hemostatic stewardship: Evaluation of romiplostim for treatment of thrombocytopenia at a large academic medical center. J Oncol Pharm Pract. 2024 PMID: 37132025; Cite
- Avatrombopag-induced lactic acidosis in a patient with severe thrombocytopenia. BMJ Case Rep. 2023 PMID: 38061849; Cite
- A case of successful treatment with eltrombopag for severe immune-related thrombocytopenia induced by atezolizumab:Case report. J Med Invest. 2023 PMID: 37940542; Cite
- Analysis of clinical characteristics and treatment efficacy in two pediatric cases of ANKRD26-related thrombocytopenia. Platelets. 2023 PMID: 37852929; Cite
- Treatment of immune thrombocytopenia during pregnancy with thrombopoietin receptor agonists. Br J Haematol. 2023 PMID: 37830251; Cite
- [A case of rectal cancer with immune thrombocytopenic purpura that achieved a complete response to continued chemotherapy with eltrombopag]. Nihon Shokakibyo Gakkai Zasshi. 2023 PMID: 37821375; Cite
- Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in The Netherlands (TRAPeze Netherlands study). Hematology. 2023 PMID: 37818773; Cite
- Immunomodulation with romiplostim as a second-line strategy in primary immune thrombocytopenia: The iROM study. Br J Haematol. 2023 PMID: 37735543; Cite
- Children with Chronic Immune Thrombocytopenia Exhibit High Expression of Human Endogenous Retroviruses TRIM28 and SETDB1. Genes (Basel). 2023 PMID: 37628621; Cite
- Splenic Artery Embolization in a Patient With Intracranial Hemorrhage Due to Refractory Persistent Immune Thrombocytopenia. J Pediatr Hematol Oncol. 2023 PMID: 37526353; Cite
- Avatrombopag increased platelet count in a patient with chronic immune thrombocytopenia refractory to multiple lines of treatment. Blood Coagul Fibrinolysis. 2023 PMID: 37395226; Cite
- A phase 3, randomized, double-blind, active-controlled trial evaluating efficacy and safety of avatrombopag versus eltrombopag in ITP. Br J Haematol. 2023 PMID: 37339869; Cite
- Early initiation of second-line therapy in primary immune thrombocytopenia: insights from real-world evidence. Ann Hematol. 2023 PMID: 37300567; Cite
- Plasma gastric biomarker evaluation with avatrombopag dosing in patients with chronic immune thrombocytopenia in phase 3 trials. Br J Haematol. 2023 PMID: 37280093; Cite
- A successful management of refractory immune thrombocytopenic purpura with Eltrombopag during pregnancy complicated with superimposed preeclampsia. Oxf Med Case Reports. 2023 PMID: 37260727; Cite
- Combining thrombopoietin receptor agonists with immunosuppressive drugs in adult patients with multirefractory immune thrombocytopenia, an update on the French experience. Br J Haematol. 2023 PMID: 37247631; Cite
- Pediatric immune thrombocytopenia: a focus on eltrombopag as second-line therapy. Hematology. 2023 PMID: 37199369; Cite
- Outcomes of switching to avatrombopag following treatment failure with eltrombopag in paediatric immune thrombocytopenia: A real-world study in China. Br J Haematol. 2023 PMID: 37188335; Cite
- Sustained response off treatment in eltrombopag for children with persistent/chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China. Br J Haematol. 2023 PMID: 37128832; Cite
- Current Concepts in the Diagnosis and Management of Adult Primary Immune Thrombocytopenia: Our Personal View. Medicina (Kaunas). 2023 PMID: 37109773; Cite
- Safety Profile of Eltrombopag in Different Age Groups: An Analysis of Real-World Pharmacovigilance and Randomized Clinical Trials. Clin Pharmacol Ther. 2023 PMID: 37087633; Cite
- Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia. Expert Rev Hematol. 2023 PMID: 37039010; Cite
- Additional efficacy analysis of avatrombopag phase III data for the treatment of adults with immune thrombocytopenia. Platelets. 2023 PMID: 37013676; Cite
540 possible systematic reviews found at PubMed. Will restrict search terms to title words and MeSH major terms.
621 possible systematic reviews found from PubMed (View at PubMed)
Click here to modify your search at PubMed.
- Is Immune Thrombocytopenia and its Treatment Associated with Sarcopenia? Niger J Clin Pract. 2024 PMID: 38409145 (DARE summary if available); Cite
- Thrombopoietin receptor agonists use and risk of thrombotic events in patients with immune thrombocytopenic purpura: A systematic review and meta‑analysis of randomized controlled trials. Biomed Rep. 2024 PMID: 38357229 (DARE summary if available); Cite
- A Review on Romiplostim Mechanism of Action and the Expressive Approach in E. coli. Recent Pat Biotechnol. 2024 PMID: 38282441 (DARE summary if available); Cite
- Long-term eltrombopag in children with chronic immune thrombocytopenia: A single-centre extended real-life observational study in China. Br J Haematol. 2024 PMID: 38087811 (DARE summary if available); Cite
- Avatrombopag for adults with early versus chronic immune thrombocytopenia. Am J Hematol. 2024 PMID: 38063420 (DARE summary if available); Cite
- Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: Primary, final, and ad-hoc analyses of the Phase II TAPER trial. Am J Hematol. 2024 PMID: 38014779 (DARE summary if available); Cite
- Efficacy and safety of eltrombopag in the treatment of immune thrombocytopenia patients with hepatitis B virus infection: A prospective, multicenter, single arm, phase II trial. Am J Hematol. 2024 PMID: 37883528 (DARE summary if available); Cite
- Antithrombotic and hemostatic stewardship: Evaluation of romiplostim for treatment of thrombocytopenia at a large academic medical center. J Oncol Pharm Pract. 2024 PMID: 37132025 (DARE summary if available); Cite
- Avatrombopag-induced lactic acidosis in a patient with severe thrombocytopenia. BMJ Case Rep. 2023 PMID: 38061849 (DARE summary if available); Cite
- A case of successful treatment with eltrombopag for severe immune-related thrombocytopenia induced by atezolizumab:Case report. J Med Invest. 2023 PMID: 37940542 (DARE summary if available); Cite
- Analysis of clinical characteristics and treatment efficacy in two pediatric cases of ANKRD26-related thrombocytopenia. Platelets. 2023 PMID: 37852929 (DARE summary if available); Cite
- Treatment of immune thrombocytopenia during pregnancy with thrombopoietin receptor agonists. Br J Haematol. 2023 PMID: 37830251 (DARE summary if available); Cite
- [A case of rectal cancer with immune thrombocytopenic purpura that achieved a complete response to continued chemotherapy with eltrombopag]. Nihon Shokakibyo Gakkai Zasshi. 2023 PMID: 37821375 (DARE summary if available); Cite
- Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in The Netherlands (TRAPeze Netherlands study). Hematology. 2023 PMID: 37818773 (DARE summary if available); Cite
- Immunomodulation with romiplostim as a second-line strategy in primary immune thrombocytopenia: The iROM study. Br J Haematol. 2023 PMID: 37735543 (DARE summary if available); Cite
- Children with Chronic Immune Thrombocytopenia Exhibit High Expression of Human Endogenous Retroviruses TRIM28 and SETDB1. Genes (Basel). 2023 PMID: 37628621 (DARE summary if available); Cite
- Splenic Artery Embolization in a Patient With Intracranial Hemorrhage Due to Refractory Persistent Immune Thrombocytopenia. J Pediatr Hematol Oncol. 2023 PMID: 37526353 (DARE summary if available); Cite
- Avatrombopag increased platelet count in a patient with chronic immune thrombocytopenia refractory to multiple lines of treatment. Blood Coagul Fibrinolysis. 2023 PMID: 37395226 (DARE summary if available); Cite
- A phase 3, randomized, double-blind, active-controlled trial evaluating efficacy and safety of avatrombopag versus eltrombopag in ITP. Br J Haematol. 2023 PMID: 37339869 (DARE summary if available); Cite
- Early initiation of second-line therapy in primary immune thrombocytopenia: insights from real-world evidence. Ann Hematol. 2023 PMID: 37300567 (DARE summary if available); Cite
- Plasma gastric biomarker evaluation with avatrombopag dosing in patients with chronic immune thrombocytopenia in phase 3 trials. Br J Haematol. 2023 PMID: 37280093 (DARE summary if available); Cite
- A successful management of refractory immune thrombocytopenic purpura with Eltrombopag during pregnancy complicated with superimposed preeclampsia. Oxf Med Case Reports. 2023 PMID: 37260727 (DARE summary if available); Cite
- Combining thrombopoietin receptor agonists with immunosuppressive drugs in adult patients with multirefractory immune thrombocytopenia, an update on the French experience. Br J Haematol. 2023 PMID: 37247631 (DARE summary if available); Cite
- Pediatric immune thrombocytopenia: a focus on eltrombopag as second-line therapy. Hematology. 2023 PMID: 37199369 (DARE summary if available); Cite
- Outcomes of switching to avatrombopag following treatment failure with eltrombopag in paediatric immune thrombocytopenia: A real-world study in China. Br J Haematol. 2023 PMID: 37188335 (DARE summary if available); Cite
- Sustained response off treatment in eltrombopag for children with persistent/chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China. Br J Haematol. 2023 PMID: 37128832 (DARE summary if available); Cite
- Current Concepts in the Diagnosis and Management of Adult Primary Immune Thrombocytopenia: Our Personal View. Medicina (Kaunas). 2023 PMID: 37109773 (DARE summary if available); Cite
- Safety Profile of Eltrombopag in Different Age Groups: An Analysis of Real-World Pharmacovigilance and Randomized Clinical Trials. Clin Pharmacol Ther. 2023 PMID: 37087633 (DARE summary if available); Cite
- Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia. Expert Rev Hematol. 2023 PMID: 37039010 (DARE summary if available); Cite
- Additional efficacy analysis of avatrombopag phase III data for the treatment of adults with immune thrombocytopenia. Platelets. 2023 PMID: 37013676 (DARE summary if available); Cite
|
You found 50 or more articles.
Thursday, 28 Mar 2024 06:20:32 at SUMSearch
|